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352 O’Callaghan et al February 2015inﬂuences outcomes; however, we think that its effects in this
situation are minimal as we had performed more than 400
fenestrated repairs alone before the ﬁrst staged procedure
(meaning that technical improvements were unlikely to be
relevant), and the principles of multimodal optimization of
spinal perfusion were fully embedded in out institution by
2008, as described in our previous publication (meaning
that there were no ancillary anesthetic or perioperative mea-
sures instituted that would account for the improvement in
outcome with staged repair).8 A related confounder is that
of selection bias, the more extensive type II repairs being
selected for staging, which is reﬂected in the increased pro-
portion of aorta excluded in the two-stage group. However,
the bias in this case would serve only to heighten the risk
with staging, making the lower spinal ischemia rate associ-
ated with this technique all the more encouraging.
CONCLUSIONS
Staged repair appears both to protect against SCI and
to enhance overall survival in extensive aortic repair.
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at www.jvascsurg.org.DISCUSSIONDr Julie Ann Freischlag (Sacramento, Calif). I have one
initial question. Did you have patients that were scheduled to
have this two stage repair, you did the ﬁrst stage, and for whateverreason they never came back to the second? Did you lose any to
death or other issues between the two stages that were not
included in your review?
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second stage. Two patients suffered a rupture in the intervening
period. One of those patients, unfortunately, expired; and the sec-
ond patient had a successful open repair followed by a successful
fenestrated endovascular aortic aneurysm repair.
Dr Freischlag. Did that change your interval thoughts, or are
you still doing the same amount of time?
Dr O’Callaghan. There is about a 6 to 12 week lag before
we get the fenestrated device designed and ready, so our prac-
tice, when we decide to undertake a staged repair, is to perform
the thoracic endograft as soon as feasible, and in the meantime
we are ordering and constructing the customized fenestrated
device.
Dr William Quinones Baldrich (Los Angeles, Calif). Very
nice presentation and analysis of a large experience. These results
support my impression that staging reduces the risk of paraplegia.
Interval rupture is a well-documented risk. Is there any particular
morphology of the aneurysm that would make you want to repair
it in one stage or reduce the time between stages?
Dr O’Callaghan. Well, clearly, symptomatic patients deserve
an early repair. And as off the shelf devices become more feasible,
then the interval between the staged repairs will again become
shorter.
We know from experimental evidence by Dr Etz’s group that
the time for collateralization is approximately 5 to 7 days. So in
terms of how long we need to leave this, I would say 2 to 3 weeks
may be optimum; but I don’t think anyone knows the exact answer
to that question.
Dr Amy Reed (Hershey, Pa). You touched early on in the pre-
sentation about the length of time for collateralization. You
mentioned 6 to 12 weeks. Could you glean anything from the
data that you had as to the time frame of how long to wait? If
we wait longer, is it better, do patients develop more collateraliza-
tion? That would be assumed.
And then also as far as the extent of where you covered the
thoracic aorta, did you plan to stop at a certain level? Did you al-
ways stop before T10? What was your choice for that?
Dr O’Callaghan. When we implant a thoracic device, we’re
cognizant of leaving enough seal room for the fenestrated compo-
nent and balancing that with the need to cover enough aorta to
stimulate collateralization.
As to the time to collateralization, I don’t think anyone knows
the answer to that question. The numbers are too small and the
times are too heterogeneous to derive any ideal time. I suspect
that the time to collateralization may be much shorter than 6 to
12 weeks. Unfortunately, because of the nature of customized de-
vices, there is a 6 to 12 week lag and that, to an extent, determines
our present time delay.
Dr Thomas Lindsay (Toronto, Ontario, Canada). I’d like to
congratulate the authors as well. I think this is a very seminal piece
of work.
I have a couple of questions:
First of all, we know that when you do a two staged proce-
dure, the ﬁrst surgical stage really doesn’t take very long for the
thoracic piece. What do you think is most important, the inﬂu-
ence of the length of that surgery vs the length of time it takes
to put in a whole device, including the thoracic piece and the
custom?
The second question you didn’t mention is temporary para-
plegia. And as you know, many of these patients have temporary
paraparesis treated with elevating the blood pressure and spinal
cord drainage. And you didn’t touch on the evidence, or the inci-
dence of that, in both of those and maybe you could tell us a little
bit about that.
And then what sort of spinal cord protocol have you been
following for those with temporary paraparesis, and did you see
more in the ﬁrst stage or did you see more in the second stage?
Dr O’Callaghan. We saw one case of temporary paraplegia
following the ﬁrst stage. When we see weakness following the
operation, we endeavor to raise the mean arterial pressure over100 mm Hg, and we try and drop the spinal pressure at 10 or
below to try and alleviate that ischemia.
And in terms then of the paresis, approximately one ﬁfth of the
patients in the single stage group developed permanent paraplegia,
the rest resolved. And all the cases in the two stage group
completely resolved.
And those mirror Dr Eagleton’s publication last year on our
complete experience across our entire population of fenestrated
and branched patients.
Dr Ian Loftus (London, United Kingdom). Just to press on
Tom’s point, was there a difference in spinal drain protection pro-
tocol between those undergoing a single stage and those undergo-
ing the second stage of their staged repair, or are they managed
identically?
Dr O’Callaghan. That was one of the reasons why we chose a
relatively contemporary cohort of patients. In the period we chose,
2008 onwards, there have been no signiﬁcant changes in terms of
our algorithm. All the patients have a spinal drain inserted preop-
eratively. The spinal drain is set at 10 intraoperatively and main-
tained at that point for 2 days; unless the patient develops
ischemia, at which point the spinal drain is lowered and the
mean arterial pressure is raised. And there is absolutely no differ-
ence in terms of how we manage these patients intraoperatively
or postoperatively.
Dr Stephan Haulon (Lille, France). I try to stage as much as
possible also my type II endo repairs. The issue is to ﬁnd a sealing
zone in the middle of the descending thoracic aorta. In most of the
patients, we don’t ﬁnd it because the largest diameter endografts
we have today are 46 mm. Do you think we should design a
new type of endograft just for those two staged procedures?
Dr O’Callaghan. I think when you look into the experi-
mental work on this, these patients need some kind of an ischemic
stress. So designing an endograft that would lead to a threshold of
ischemia without causing complete paralysis seems intuitive. How-
ever, in our experience using commercial devices, we still ﬁnd a
beneﬁt to staging.
Dr Timothy A. Chuter (San Francisco, Calif). I wonder
about the potential for selection bias. How did you select the pa-
tients for the different approaches?
I would also like to comment on the nature of the two stage
procedure whereby you’re hoping for some aneurysm thrombosis,
as a stimulus to collateral formation, but not too much, and you
can’t really predict which it’s going to be. You’re left with two gen-
eral anesthetics, two spinal drain insertions, and all the associated
morbidity without a predictable beneﬁt. Have you considered
the use of a “perfusion-preserving cuff”?
Dr O’Callaghan. Dr Ivancic has published on his perfusion
preservation cuff on a series of 10 patients, and they found three
of those patients developed at least transient ischemia, which is a
rate of 30%. I mean, I think there are many ways to elicit this
stress response and there probably is no ideal method. Certainly,
in our experience, staging makes a lot of sense. To complete a
complete type II endovascular repair, it takes a number of hours,
and so anything that you can do to try and reduce that again
would seem to make intuitive sense, without having direct evi-
dence for it.
In the earlier years, we were staging less patients and per-
forming more of them as a single stage. However, in the last
3 years, most of our type II repairs are staged. So there is a
bias in that respect. But you saw from our results that the
two stage patients have signiﬁcantly more of the aorta covered
by the endovascular device, and therefore they would theoreti-
cally increase risk of spinal cord ischemia. Nonetheless, they
experienced increased survival and reduced overall rates of
ischemia. The perioperative management algorithm has not
changed since 2008.
Have we got everything correct? I don’t think so. We’re still
getting some rates of paresis. I think that probably relates to
your question about how much of the aorta we covered and
what kind of stress response we do elicit. We have no control
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much of the artery we cover in one cohort, we know how much we
can safely cover, I don’t think that question can be answered
correctly.
Dr Jan Blankensteijn (Amsterdam, Netherlands). Just a quick
practical question. Do you use a certain length of coverage as a
threshold to determine in your current practice to stage the proce-
dure, or not?Dr O’Callaghan. No, we have no ﬁxed number. From the
EUROSTAR data, a length of 200 cm would seem to indicate
that that’s one threshold. So again, that might be a number
you have in your head. But overall when we do the staged proce-
dure, we have the overall repair in mind and we are very cogni-
zant of leaving enough thoracic endograft so that we can safely
dock our custom device into it and achieve a durable seal between
devices.
